CORCEPT THERAPEUTICS INC (CORT) Form 8-K — Nov 3, 2026
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, up 64% year over year, with net income of $126.8 million ($1.01 diluted EPS vs $0.16 a year ago). The company reiterated 2026 revenue guidance of $1.1-$1.2 billion. Newly launched Lifyorli (relacorilant) hit $91.4 million in quarterly revenue, up 92% sequentially, with over 2,300 patients treated and 1,700 prescribers since its April launch. Korlym revenue grew 19% to $249.1 million.
Key figures
- Eps
- 1.01
- Revenue
- 340472000
- Guidance
- Reiterated 2026 revenue guidance of $1.1-$1.2 billion
- Net Income
- 126778000
- Revenue Yoy
- 64%
- Total Assets
- 1034027000
- Cash Position
- 662307000
- Buyback q3
- $43.7 million of common stock repurchased
- Bella part a orr
- 59%
- Korlym revenue q3
- $249.1 million (+19% QoQ)
- Lifyorli revenue q3
- $91.4 million (+92% QoQ)
- Lifyorli prescribers
- 1700
- Bevacizumab naive orr
- 66%
- Bevacizumab naive pfs
- 8.1 months
- Bella part a 6month os
- 88%
- Bella part a median pfs
- 7.2 months
- Monarch fibrosis improvement
- 19% at 48 weeks
- Lifyorli patients since launch
- 2300
- Pdufa date relacorilant cushing
- December 17, 2026
- Dazals year1 death risk reduction
- 84% (HR 0.16, p=0.0009)
- Dazals year2 death risk reduction
- 87% (HR 0.13, p<0.0001)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.